| MeSH term | MeSH ID | Detail |
|---|---|---|
| Alzheimer Disease | D000544 | 76 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Edema | D004487 | 152 associated lipids |
(e,e,e,e)-squalene
(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
Cross Reference
Introduction
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with (e,e,e,e)-squalene?
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
PubChem Associated disorders and diseases
What pathways are associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with (e,e,e,e)-squalene?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with (e,e,e,e)-squalene?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with (e,e,e,e)-squalene
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Van Leusden H and Villee CA | The de novo synthesis of sterols and steroids from acetate by preparations of human term placenta. | 1965 | Steroids | pmid:5857495 |
| Cattel L et al. | Drug design based on biosynthetic studies: synthesis, biological activity, and kinetics of new inhibitors of 2,3-oxidosqualene cyclase and squalene epoxidase. | 1989 Mar-May | Steroids | pmid:2678608 |
| Lewis D et al. | Enzyme inhibition during the conversion of squalene to cholesterol. | 1995 | Steroids | pmid:7482633 |
| Dennick RG | The intracellular organisation of cholesterol biosynthesis. A review. | 1972 | Steroids Lipids Res | pmid:4572325 |
| Abe I | [Bioorganic chemistry of squalene cyclase]. | 1994 | Tanpakushitsu Kakusan Koso | pmid:8090933 |
| Yamamoto S | [Oxidative cyclization of squalene. Biosynthesis of sterols]. | 1970 | Tanpakushitsu Kakusan Koso | pmid:4912088 |
| Corey EJ and Yamamoto H | Correlation of a protosterol from 20,21-dehydro-2,3-oxidosqualene and 2,3-oxidosqualene-sterol cyclase with dihydrolanosterol. | 1970 | Tetrahedron Lett. | pmid:5447652 |
| Rees HH et al. | Cyclization of 2,3-oxidosqualene to cycloartenol in a cell-free system from higher plants. | 1968 | Tetrahedron Lett. | pmid:5640097 |
| Montana M et al. | Safety review: squalene and thimerosal in vaccines. | 2010 Nov-Dec | Therapie | pmid:21176760 |
| Dorea JG | Safety of thimerosal in vaccines: for whom and how many doses? | 2011 Mar-Apr | Therapie | pmid:23189333 |
| Achiraman S et al. | Increased squalene concentrations in the clitoral gland during the estrous cycle in rats: an estrus-indicating scent mark? | 2011 | Theriogenology | pmid:21924481 |
| Alghisi F et al. | Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. | 2011 | Thorax | pmid:21228426 |
| Miettinen TA | Hyperlipoproteinemia--relation to platelet lipids, platelet function and tendency to thrombosis. | 1974 | Thromb. Res. | pmid:4367389 |
| Ali HM et al. | Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol. | 2014 | Thyroid | pmid:23885719 |
| Chida N and Okamura T | Increased cholesterol-biosynthesis in familial hypercholesterolemia. | 1971 | Tohoku J. Exp. Med. | pmid:5140375 |
| Torinuki W et al. | Effect of beta-carotene on ultraweak chemiluminescence of UVB-irradiated squalene. | 1982 | Tohoku J. Exp. Med. | pmid:7101278 |
| Hayakawa K and Matsuo I | Effects of PUVA therapy on skin surface lipids: skin surface lipid peroxidation in psoriasis vulgaris and its biological significance. | 1986 | Tokai J. Exp. Clin. Med. | pmid:3672560 |
| Yockel S and Schatz GC | Dynamic QM/MM: a hybrid approach to simulating gas-liquid interactions. | 2012 | Top Curr Chem | pmid:21506003 |
| Uchino T et al. | Potent protecting effects of Catuaba (Anemopaegma mirandum) extracts against hydroperoxide-induced cytotoxicity. | 2004 | Toxicol In Vitro | pmid:15046771 |
| Flint OP et al. | Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. | 1997 | Toxicol. Appl. Pharmacol. | pmid:9221828 |
| Kuroda Y et al. | Distinctive patterns of autoimmune response induced by different types of mineral oil. | 2004 | Toxicol. Sci. | pmid:14718649 |
| Sunthornandh P and Ratanabanangkoon K | A comparative study of three vehicles on antibody responses against elapid snake neurotoxin immunogens. | 1994 | Toxicon | pmid:8079368 |
| Johnson WS | Nonenzymic biogenetic-like olefinic cyclizations. | 1967 | Trans N Y Acad Sci | pmid:5237390 |
| Gylling H et al. | Cholesterol synthesis prevails over absorption in metabolic syndrome. | 2007 | Transl Res | pmid:17543849 |
| Siirtola A et al. | Cholesterol absorption and synthesis in pediatric kidney, liver, and heart transplant recipients. | 2006 | Transplantation | pmid:16477216 |
| Moebius FF et al. | Genetic defects in postsqualene cholesterol biosynthesis. | 2000 | Trends Endocrinol. Metab. | pmid:10707051 |
| Laursen AB | [Dangerous adjuvant in swine influenza vaccine]. | 2009 | Ugeskr. Laeg. | pmid:19866499 |
| Bruun Laursen A | [Catastrophic consequences of Pandemrix swine flu vaccine containing squalene]. | 2013 | Ugeskr. Laeg. | pmid:23833781 |
| Mølbak K | [Squalene unlikely sinner]. | 2013 | Ugeskr. Laeg. | pmid:23833782 |
| Ihara T | [Evaluation of alum-adjuvanted whole virus influenza vaccine and future aspects of influenza A (H1N1) 2009 vaccine]. | 2010 | Uirusu | pmid:20848866 |
| Vendt VP | [Studies in the field of chemistry, biochemistry and photobiochemistry of sterols]. | 1975 Sep-Oct | Ukr Biokhim Zh | pmid:1105921 |
| Sanina OL and Datsenko ZM | [Sterol composition of sarcolemma in normal rabbits and in experimental muscular dystrophy]. | 1975 Nov-Dec | Ukr Biokhim Zh | pmid:1202710 |
| PerederiÄ OF and Morozova RP | [Squalene and sterols of rat stomach tissue and the effect of acetylsalicylic acid on their content]. | 1978 Nov-Dec | Ukr. Biokhim. Zh. | pmid:749299 |
| Morozova RP et al. | [Separation of lipid extract from animal blood and tissues and isolation of squalene and sterols from it]. | 1982 Jul-Aug | Ukr. Biokhim. Zh. | pmid:7135500 |
| Dediukhina EG and Eroshin VK | [Hydrocarbon biosynthesis by microorganisms]. | 1973 Nov-Dec | Usp Sovrem Biol | pmid:4593530 |
| Morel S et al. | Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. | 2011 | Vaccine | pmid:21256188 |
| Decaro N et al. | Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. | 2011 | Vaccine | pmid:21272607 |
| de Roux A et al. | Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. | 2006 | Vaccine | pmid:16288937 |
| Singh M et al. | A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. | 2006 | Vaccine | pmid:16300864 |
| Puig-Barberà J et al. | Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. | 2004 | Vaccine | pmid:15530669 |
| Tritto E et al. | Mechanism of action of licensed vaccine adjuvants. | 2009 | Vaccine | pmid:19200813 |
| Ansaldi F et al. | Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. | 2009 | Vaccine | pmid:19200846 |
| Del Giudice G et al. | An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. | 2006 | Vaccine | pmid:16464520 |
| Cataldo DM and Van Nest G | The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. | 1997 | Vaccine | pmid:9364672 |
| Barnett SW et al. | Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. | 1997 | Vaccine | pmid:9234536 |
| Romera SA et al. | Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle. | 2000 | Vaccine | pmid:10924795 |
| Schultze V et al. | Safety of MF59 adjuvant. | 2008 | Vaccine | pmid:18462843 |
| Boyce TG et al. | Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. | 2000 | Vaccine | pmid:10930676 |
| O'Hagan DT et al. | Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. | 2000 | Vaccine | pmid:10699327 |
| Keitel W et al. | Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. | 2010 | Vaccine | pmid:19835829 |
| Vesikari T et al. | MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. | 2009 | Vaccine | pmid:19840662 |
| Hilgers LA et al. | A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. | 1994 | Vaccine | pmid:8085385 |
| Hilgers LA et al. | A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. | 1994 | Vaccine | pmid:8085386 |
| Byars NE et al. | Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. | 1994 | Vaccine | pmid:8165851 |
| Faenzi E et al. | One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. | 2012 | Vaccine | pmid:22521851 |
| Hatz C et al. | A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. | 2012 | Vaccine | pmid:22626675 |
| Precioso AR et al. | A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. | 2011 | Vaccine | pmid:21945258 |
| Pariani E et al. | Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. | 2011 | Vaccine | pmid:21974995 |
| Andrews NJ et al. | Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. | 2011 | Vaccine | pmid:21875635 |
| Barchfeld GL et al. | The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. | 1999 | Vaccine | pmid:10067675 |
| Iorio AM et al. | Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. | 2012 | Vaccine | pmid:22245606 |
| Frey SE et al. | Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. | 2010 | Vaccine | pmid:20619382 |
| Dupuis M et al. | Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. | 1999 | Vaccine | pmid:10519932 |
| Ott G et al. | Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. | 1995 | Vaccine | pmid:8578842 |
| Heineman TC et al. | A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. | 1999 | Vaccine | pmid:10438046 |
| De Donato S et al. | Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. | 1999 | Vaccine | pmid:10462245 |
| Tsai T et al. | Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. | 2010 | Vaccine | pmid:19969117 |
| Greer CE et al. | The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. | 2000 | Vaccine | pmid:11137233 |
| Pietrella D et al. | A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. | 2010 | Vaccine | pmid:20038431 |
| Candela S et al. | An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one. | 2013 | Vaccine | pmid:22766247 |
| Langley JM et al. | Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. | 2012 | Vaccine | pmid:22469860 |
| Fukase H et al. | Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. | 2012 | Vaccine | pmid:22472791 |
| Hatz C et al. | A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. | 2012 | Vaccine | pmid:22446638 |
| Süli J et al. | Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. | 2004 | Vaccine | pmid:15308373 |
| BenÃsek Z et al. | Experimental squalene adjuvant. II. Harmlessness and local reactogenity. | 2004 | Vaccine | pmid:15308374 |
| O'Hagan DT et al. | The mechanism of action of MF59 - an innately attractive adjuvant formulation. | 2012 | Vaccine | pmid:22682289 |
| Okike IO et al. | The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. | 2011 | Vaccine | pmid:21742005 |
| Reynales H et al. | A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. | 2012 | Vaccine | pmid:22902681 |
| Ventura R et al. | Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. | 2013 | Vaccine | pmid:22884665 |
| Della Cioppa G et al. | Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. | 2011 | Vaccine | pmid:21906647 |
| Moro ML et al. | A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two. | 2013 | Vaccine | pmid:22885015 |
| Fox CB et al. | Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. | 2011 | Vaccine | pmid:21906648 |
| Radosević K et al. | Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. | 2008 | Vaccine | pmid:18514980 |
| Baldo V et al. | MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. | 2007 | Vaccine | pmid:17383057 |
| Black S et al. | Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. | 2010 | Vaccine | pmid:20813217 |
| Calabro S et al. | The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. | 2013 | Vaccine | pmid:23684834 |
| Skeiky YA et al. | Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. | 2002 | Vaccine | pmid:12213399 |
| de Bruijn I et al. | Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. | 2007 | Vaccine | pmid:18063446 |
| Stephenson I et al. | Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. | 2003 | Vaccine | pmid:12639491 |
| Tetsutani K and Ishii KJ | Adjuvants in influenza vaccines. | 2012 | Vaccine | pmid:23084848 |
| Cristiani C et al. | Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. | 2011 | Vaccine | pmid:21396903 |
| Meier S et al. | Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. | 2011 | Vaccine | pmid:21419775 |
| Bråve A et al. | Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. | 2007 | Vaccine | pmid:17707956 |
| Parretta E et al. | Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. | 2011 | Vaccine | pmid:21406267 |
| Ansaldi F et al. | Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. | 2008 | Vaccine | pmid:18294741 |
| Segura-Velázquez R et al. | Influenza vaccine: development of a novel intranasal and subcutaneous recombinant adjuvant. | 2013 | Vaccine | pmid:23746458 |
| Puig-Barberà J et al. | MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. | 2013 | Vaccine | pmid:23731629 |
| Van Buynder PG et al. | The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. | 2013 | Vaccine | pmid:23933368 |
| Vinay TN et al. | Inactivated vaccine against viral hemorrhagic septicemia (VHS) emulsified with squalene and aluminum hydroxide adjuvant provides long term protection in olive flounder (Paralichthys olivaceus). | 2013 | Vaccine | pmid:23896420 |
| Poder A et al. | An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. | 2014 | Vaccine | pmid:24252703 |